Afya Ltd. (AFYA)
Is Afya (AFYA) Stock Outpacing Its Consumer Discretionary Peers This Year?
Here is how Afya (AFYA) and American Public Education (APEI) have performed compared to their sector so far this year.
Are Investors Undervaluing Afya (AFYA) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
New Strong Buy Stocks for June 23rd
DPMLF, EGO, AFYA, ALSN and HMN have been added to the Zacks Rank #1 (Strong Buy) List on June 23, 2025.
Afya Limited Continues To Grow, But Limits Are Also Evident
Afya Limited delivered solid Q1 results with 16% YoY revenue growth, driven by acquisitions and organic expansion, and reported strong seasonal margins. Valuation at 11–13x earnings appears fair but not compelling, given long-term risks of market saturation and increased competition in Brazil's medical education sector. Long-term concerns persist as Brazil rapidly increases its doctor supply, potentially pressuring AFYA's enrollment and pricing power in the future.
Afya Limited (AFYA) Q1 2025 Earnings Call Transcript
Afya Limited (NASDAQ:AFYA ) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Virgilio Gibbon - Chief Executive Officer Luis Andre Blanco - Chief Financial Officer Conference Call Participants Flavio Yoshida - Bank of America Lucca Marquezini - Itau Mauricio Cepeda - Morgan Stanley Marcelo Santos - JPMorgan Unidentified Company Representative Thank you for joining us for Afya's conference call. I'm here today with Afya's CEO, Virgilio Gibbon; and our CFO, Luis Andre Blanco.
Afya (AFYA) Surpasses Q4 Earnings and Revenue Estimates
Afya (AFYA) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.36 per share a year ago.
Afya to Expand Medical Education Reach With FUNIC Acquisition
AFYA has announced a share purchase agreement to acquire 100% of FUNIC.
Afya Continues To Be An Opportunity Even After Brazil's Depreciation
Afya's 3Q24 results showed 12% organic revenue growth and 16% overall growth, driven by the Unidom acquisition and strong performance in medical education and software segments. The company leveraged its cost structure, achieving a 300bps increase in adj EBITDA margin and a 68% YoY net income growth despite higher financial costs. Afya's valuation remains attractive, with a P/E of 11x and a potential yield of 20% in a few years, justifying a Buy rating.
Afya (AFYA) Q3 Earnings Miss Estimates
Afya (AFYA) came out with quarterly earnings of $0.32 per share, missing the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $0.28 per share a year ago.
Is the Options Market Predicting a Spike in AFYA Stock?
Investors need to pay close attention to AFYA stock based on the movements in the options market lately.
Afya: Q2 2024 Was Not Surprising, Still An Opportunity Despite New Info On Market Supply
Afya's Q2 2024 results showed stable operations with 14% revenue growth, driven by increased enrollment and tuition, and improved operating margins. A favorable Supreme Court ruling on medical seat openings and new financing from the IFC are positive developments for Afya. Despite short-term stability, long-term concerns arise due to potential oversupply in Brazil's medical education and profession markets.
Afya (AFYA) Surpasses Q2 Earnings and Revenue Estimates
Afya (AFYA) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.37 per share. This compares to earnings of $0.29 per share a year ago.
